Daily Bio News Summary — 2026-10-29: A Q3 earnings wall, five clinical verdicts, and a quieter policy tape

Thursday’s harvest is a 15-item batch drawn mainly from Fierce Pharma, Fierce Biotech, BioSpace, Reuters Biopharma and BioPharma Dive, with single items from Pharmaphorum and Reuters. By category the batch splits roughly into five earnings stories, six clinical or pipeline items, two deal/manufacturing items, one public-health funding item and one governance appointment. What it is not is a deal tape: there is no mega-merger in this set, and no new FDA approval.

The Q3 earnings wall

Five of the fifteen items are third-quarter results, and the through-line is that the large-cap tape is being carried by a small number of franchises.

Merck topped third-quarter estimates as Keytruda and Gardasil outperformed (Reuters Biopharma, 2026-10-29). Eli Lilly’s quarter was framed around a 39% climb in revenue attributed to GLP-1 bestsellers (BioSpace, 2026-10-29). Biogen, meanwhile, was described as posting its best quarter since 2020, with the Apellis buyout cited as a driver of the return to growth (Fierce Pharma, 2026-10-28). GSK reported a mixed third quarter and used the occasion to talk through the Hibsago launch (Fierce Pharma, 2026-10-28). Roche affirmed its sales outlook despite what BioPharma Dive characterised as doubts about its future (BioPharma Dive, 2026-10-29).

Read together, the pattern is familiar: companies with a concentrated growth franchise beat and raise, while companies in transition use the call to defend guidance. The GSK item is the one to watch for launch execution rather than the headline number, since Hibsago is a new product rather than an incumbent.

Five clinical verdicts, four of them negative

The clinical news skewed hard toward failure.

Ono shelved two endocannabinoid drug studies after what the headline calls a quintuple Phase 2 failure (BioSpace, 2026-10-29). BMS walked away from an $80M neurodegeneration bet after a Phase 1 readout (Fierce Biotech, 2026-10-29). Geron’s Phase 3 stumble gave Novartis an opening to refresh its myelofibrosis bid with a post-JAK-inhibitor approach (Fierce Pharma, 2026-10-29). Against that, Genmab’s cancer bispecific delivered an early survival win that the source framed as an “exceedingly positive” Phase 3 readout — the asset carried in its $8B Merus bet (BioSpace, 2026-10-28). Ascletis, too, reported that its rival to Lilly’s Foundayo hit its goals in a Phase 2 diabetes trial (Fierce Biotech, 2026-10-29).

The asymmetry matters more than any single item. Three of the four negative items are discontinuations or write-offs of programs that were cheap to stop and expensive to continue; the two positive items are both mid-to-late-stage readouts in crowded categories (head-and-neck cancer, oral GLP-1 diabetes).

Deals and footprint

BioMarin inked a deal worth up to $475M aimed at challenging the incumbent Fabry ERT franchises (Fierce Biotech, 2026-10-29) — a rare piece of bolt-on business development in a week otherwise dominated by earnings.

On the cost side, BioSpace reported that biopharma cuts at manufacturing plants are expected to affect more than 4,000 roles (BioSpace, 2026-10-28). That is the largest single workforce figure in this batch and sits oddly next to the earnings beat narrative: revenue growth in a few franchises has not translated into manufacturing headcount.

Policy, public health and governance

The US committed $99 million to an Ebola vaccine project as cases spread in Africa (Pharmaphorum, 2026-10-29), the only public-health funding item in the set. Takeda said it will seek Japanese approval for a gastric cancer drug next year (Reuters Biopharma, 2026-10-25), a reminder that regulatory calendars outside the US are worth tracking. And Australia’s CSL named interim CEO Gordon Naylor as its new chair (Reuters Biopharma, 2026-10-25), a governance change worth flagging because the interim-CEO-to-chair move compresses two roles into one person during a transition.

What this batch is NOT telling us

• No M&A mega-deal. The largest deal item is a $475M Fabry programme; nothing in this set resembles the multi-billion platform acquisitions that dominated earlier weeks.
• No FDA approvals. The regulatory items here are a Japanese filing intent and a governance change — not an approval, a CRL or an advisory committee.
• No AI-bio items. Several AI-drug-development stories surfaced in the source homepages but were excluded at the paywall gate, so this summary under-represents that thread. Treat the silence as a harvesting artefact, not as evidence the field went quiet.
• No IPO pricing. Nothing on the new-issue tape made it into this batch.
• Earnings are not fundamentals. Five of fifteen items are quarterly prints; they say more about franchise concentration than about pipeline health.

Reading order

For a reader with five minutes, in this order:

1. Biogen’s Apellis-driven quarter (Fierce Pharma, 2026-10-28) — the clearest example of an acquisition changing a growth story.
2. Ono’s quintuple Phase 2 failure (BioSpace, 2026-10-29) — the largest single clinical setback in the batch.
3. Genmab’s Phase 3 bispecific win (BioSpace, 2026-10-28) — the counterweight, and the one item with a live regulatory path.
4. The 4,000-role manufacturing cut tally (BioSpace, 2026-10-28) — the labour-market signal behind the earnings beats.
5. Novartis’s refreshed myelofibrosis bid (Fierce Pharma, 2026-10-29) — a competitor’s failure creating a strategic opening.

How to read the underlying articles

Every item summarised here exists as a markdown file in src/content/news/ with a sourceUrl field pointing at the original article, alongside sourceName and pubDate. Where this summary characterises an item — “the largest workforce figure in this batch”, “the only public-health funding item” — that is a statement about the batch of fifteen, not about the industry on the day.

All 15 items

1. Merck tops third-quarter estimates as Keytruda, Gardasil outperform — Reuters Biopharma, 2026-10-29
2. Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers — BioSpace, 2026-10-29
3. Apellis buyout fuels Biogen’s best quarter since 2020 — Fierce Pharma, 2026-10-28
4. GSK talks through Hibsago launch as it reports out mixed Q3 — Fierce Pharma, 2026-10-28
5. Roche affirms sales outlook amid doubts about its future — BioPharma Dive, 2026-10-29
6. Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure — BioSpace, 2026-10-29
7. BMS walks away from $80M neurodegeneration bet after phase 1 — Fierce Biotech, 2026-10-29
8. Novartis refreshes myelofibrosis bid as Geron flops in ph. 3 — Fierce Pharma, 2026-10-29
9. Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout — BioSpace, 2026-10-28
10. Ascletis’ rival to Lilly’s Foundayo hits diabetes trial goals — Fierce Biotech, 2026-10-29
11. BioMarin inks up to $475M deal to challenge Fabry ERT incumbents — Fierce Biotech, 2026-10-29
12. Biopharma cuts at manufacturing plants expected to affect 4,000+ — BioSpace, 2026-10-28
13. US gives $99m for Ebola jab project as cases spread in Africa — Pharmaphorum, 2026-10-29
14. Takeda to seek Japan approval for gastric cancer drug next year — Reuters Biopharma, 2026-10-25
15. Australia’s CSL names interim CEO Gordon Naylor as new chair — Reuters Biopharma, 2026-10-25